Prognostic Value of BRAF V600 Mutations in Melanoma Patients After Resection of Metastatic Lymph Nodes

Moreau, S.; Saïag, Philippe; Aegerter, Philippe; Bosset, D.; Longvert, Christine; Hélias‐Rodzewicz, Zofia; Marin, Cristi; Peschaud, Frédérique; Chagnon, S; Zimmermann, Utte; Clérici, T.; Émile, Jean-François

doi:10.1245/s10434-012-2457-5

Cited by 87 publications

(81 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…13 Four serial sections were performed for each sample. The first section was used for histology and selection of the areas of highest histiocyte density and the 3 others for dissection at ϫ10 magnification.…”

Section: Detection Of Braf V600 Mutationsmentioning

confidence: 99%

High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses

Haroche

Charlotte

Arnaud

et al. 2012

Blood

Self Cite

613

452

View full text Add to dashboard Cite

Section: Detection Of Braf V600 Mutationsmentioning

confidence: 99%

High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses

Haroche

Charlotte

Arnaud

et al. 2012

Blood

Self Cite

613

452

View full text Add to dashboard Cite

“…11 BRAF V600E mutations were detected as previously described. 12 DNA was extracted from formalin-fixed and paraffin-embedded (FFPE) tissues after histologic detection of histiocyte-rich areas, and pyrosequencing with PyroMark Q24 (QIAGEN) was used to detect BRAF V600 mutations.…”

Section: Histology and Molecular Analysesmentioning

confidence: 99%

Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation

Haroche

Cohen‐Aubart

Émile

et al. 2013

Blood

Self Cite

483

321

View full text Add to dashboard Cite

Key Points• Treatment with vemurafenib induced a dramatic response in 3 patients with histiocytosis harboring BRAF V600E mutations.• Tumor response was observed in both Erdheim-Chester disease and Langerhans cell histiocytosis. IntroductionErdheim-Chester disease (ECD) is a rare non-Langerhans cell histiocytosis, characterized by the infiltration of tissues by foamy CD68 ϩ CD1a Ϫ histiocytes. 1 It is a systemic disease with diverse manifestations: the clinical course mainly depends on the extent and distribution of the disease, and ranges from asymptomatic bone lesions to life-threatening manifestations. 2 Rare cases of ECD associated with Langerhans cell histiocytosis (LCH) have been reported. 3 Unlike ECD, LCH histiocytes are CD1a ϩ and frequently infiltrate the epidermis in skin lesions. 4 Interferon ␣ (IFN) is generally the first choice for ECD therapy and improves survival. It should be prescribed at high dose if there is central nervous system and/or cardiovascular involvement. 2 However, long-term IFN treatment can lead to severe side effects and some patients are refractory to treatment. Moreover some patients with CNS and/or cardiovascular infiltrations develop secondary resistance to high-dose of IFN. Alternative treatments include recombinant human interleukin-1 receptor antagonist, cladribine, thyrosine kinase inhibitors, autologous hematopoietic stem cell transplantation. 2 However, the optimal second line therapeutic strategy remains to be defined, mostly because these treatments have been evaluated in only small numbers of patients. Despite recent therapeutic progress the overall mortality remains high (18% of the 84 ECD patients seen at our institution). BRAF V600E mutations have been observed in 38% to 69% of cases of LCH. [5][6][7] We recently reported BRAF V600E mutations in 54% of 24 patients with ECD. 8 Vemurafenib, an inhibitor of mutant BRAF, has shown some efficacy against 2 diseases (melanoma and hairy-cell leukemia) associated with the BRAF V600E mutation. 9,10

show abstract

“…Although not conclusive, it was suggested to be linked with rapid progression, poor RFS and short disease-specific survival (DSS) in several independent post-resection stage III melanoma data sets [10][11][12] .…”

Section: Discussionmentioning

confidence: 99%

Skeletal muscle metastasis from malignant melanoma: a case report and review of the literature

Zhu

Selvarajan

Sittampalam

et al. 2015

CRCP

View full text Add to dashboard Cite

show abstract

Prognostic Value of BRAF V600 Mutations in Melanoma Patients After Resection of Metastatic Lymph Nodes

Abstract: BRAF (V600) status could be used to stage melanoma patients with nodal deposits. Our results may also help to plan adjuvant trials in these patients, for whom the low tumor load may induce longer efficacy of BRAF-targeted therapies.

Cited by 87 publications

References 31 publications

High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses

High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses

Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation

Skeletal muscle metastasis from malignant melanoma: a case report and review of the literature

Contact Info

Product

Resources

About